Abstract Body

Background

Achieving good adherence to antiretroviral therapy (ART) and sustaining viral suppression remain challenging in adolescents living with HIV (ALHIV). However, since the large-scale rollout of dolutegravir (DTG)-based ART in pediatrics, few data are available on ART outcomes in ALHIV, particularly in West and Central Africa. We sought to evaluate the rate of virological failure (VF) and HIV-1 drug resistance (HIVDR) in ALHIV living in Benin, Cameroon, Ivory Coast and Senegal. 

Methods

Within the frame of the EVA network, the CABRILADO study was conducted among consenting ALHIV, aged 12-17 years and followed in eight pediatric centers. Clinical and sociodemographic parameters were collected. Plasma HIV-1-RNA was measured and sequencing of reverse transcriptase (RT), protease and integrase was performed on all samples with HIV-1-RNA ≥1000 cp/mL. Drug resistance mutations (DRMs) were identified and interpreted using the ANRS-MIE v35 algorithm.

Results

Overall, 638 ALHIV were enrolled (median age: 15.5 years, Interquartile range (IQR): 14.3-16.6). All were on ART, 597 (94%) of whom were receiving a DTG-based regimen (with DTG being part of their first-line regimen in 14% [86/597] of cases). VF at 1000 cp/mL, 200 cp/mL and 50 cp/mL thresholds was observed in 76 (12%), 116 (18%) and 183 (29%) ALHIV, respectively, and in 71 (12%), 107 (18%) and 166 (28%) of those receiving DTG. Factors associated with VF (≥50 cp/mL) were prior VF on ART (adjusted Odds Ratio (aOR): 2.8, 95% confidence interval (CI): 1.9-4.2), being raised by a guardian (aOR: 1.5, 95% CI:  1.0-2.3) and stunting (aOR: 1.6, 95% CI: 1.0-2.6). 

Among ALHIV experiencing VF at 1000 cp/mL, HIVDR to NRTIs, NNRTIs, protease inhibitors and integrase inhibitors were found in 31%, 27.6%, 1.7% and 6.9% of available sequences, respectively. Among ALHIV receiving DTG-regimen, 3 selected DTG-resistant viruses: R263K DRM in 1 ALHIV on 1st-line DTG, E138K+G140A+S147G+Q148R and E138K+Q148K DRM in 2 pre-treated ALHIV. More, 1 ALHIV received functional DTG monotherapy (M41L+D67N+K70R+L74I+M184V+T215F+K219Q DRM in the RT gene).

Conclusions

In this large West and Central African multi-country cohort, viral suppression of ALHIV appears encouraging (although VF exceeded 10%). Interestingly, the prevalence of integrase DRM remains low in ALHIV receiving DTG. In order to mitigate further risks of functional monotherapy, continuous monitoring of HIVDR is required in this vulnerable population requiring lifelong ART.